Detection of pancreatic cancer using serum protein profiling. Issue 8 (30th November 2012)

• Record Type: Journal Article
• Authors: Velstra, Berit; Bonsing, Bert A.; Mertens, Bart J.; van der Burgt, Yuri E. M.; Huijbers, Anouck; Vasen, Hans; Mesker, Wilma E.; Deelder, André M.; Tollenaar, Rob A. E. M.
• Is Part Of: HPB. Volume 15:Issue 8(2013:Aug.)
• Page Start: 602
• Page End: 610
• Publication Date: 2012-11-30
• Subjects: Liver -- Diseases -- Periodicals; Biliary tract -- Diseases -- Periodicals; Pancreas -- Diseases -- Periodicals; 616.362005
• DOI: 10.1111/hpb.12017
• Languages: English
• ISSNs: 1365-182X

Abstract

Abstract: Background: Currently, no suitable biomarkers for the early detection of pancreatic cancer (PC) are available. Proteins present in the serum could reflect a state of the disease. In this study, these profiles as a diagnostic marker for PC were evaluated. Methods: Serum samples were obtained from PC patients ( n = 50 calibration set, n = 39 validation set) and healthy volunteers ( n = 110 and n = 75 respectively) according to a uniform standardized collection and processing protocol. For peptide and protein isolation, automated solid‐phase extraction (SPE) with Weak Cation Exchange (WCX) magnetic beads (MB) was performed using a 96‐channel liquid handling platform. Protein profiles were obtained by mass spectrometry (MS) and evaluated by linear discriminant analysis with double cross‐validation. Results: A discriminating profile for PC has been identified, with a sensitivity of 78% and a specificity of 89% in the calibration set with an area under the curve (AUC) of 90%. These results were validated with a sensitivity of 74% and a specificity of 91% (AUC 90%). Conclusion: Serum profiles of healthy controls and PC can be discrimated between. Further research is warranted to evaluate specificity and whether this biosignature can be used for early detection in a high risk population.